Background: This study evaluated the distribution of epidermal growth factor receptor (EGFR) T790M mutations in treatment-naïve tumor and normal samples obtained from cancer patients. Methods: We utilized allele-specific PCR (AS-PCR), digital droplet PCR (ddPCR) and next generation sequencing (NGS) to detect EGFR T790M allele in several collections of tumor and normal human tissues. Results: AS-PCR analysis of treatment-naïve tumor samples revealed somatic T790M mutation in 3/394 (1%) non-small cell lung carcinomas (NSCLC) carrying the tyrosine kinase inhibitor (TKI)-sensitizing EGFR mutation, but in none of 334 NSCLC lacking EGFR exon 19 deletions (ex19del) or L858R substitutions and in none of 235 non-lung tumors. Use of highly sensitive and quantitative assays, such as ddPCR and NGS, produced a high number of T790M-specific signals even in presumably T790M-negative DNA specimens. This background noise was evidently higher in degraded DNA isolated from formalin-fixed paraffin-embedded tissues as compared to high molecular weight DNA. A combination of AS-PCR, ddPCR and NGS revealed mosaic EGFR T790M allele in 2/68 (3%) NSCLC treated with the first-generation TKI. Both these tumors produced evident and durable response to gefitinib. Conclusion: Detection of mosaic EGFR T790M mutation in treatment-naïve samples may be compromised by yet unresolved technical issues and may have limited clinical value.

Keywords:
EGFR, T790M, Tyrosine kinase inhibitors, Treatment resistance, Intratumoral heterogeneity
1.
Russo A, Franchina T, Ricciardi GR, et al.: A decade of EGFR inhibition in EGFR-mutated non-small cell lung cancer (NSCLC): Old successes and future perspectives. Oncotarget 2015;6:26814-26825.
2.
Piotrowska Z, Sequist LV: Epidermal growth factor receptor-mutant lung cancer: New drugs, new resistance mechanisms, and future treatment options. Cancer J 2015;21:371-377.
3.
Pao W, Miller VA, Politi KA, et al.: Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005;2:e73.
4.
Yun CH, Mengwasser KE, Toms AV, et al.: The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA 2008;105:2070-2075.
5.
Chen HJ, Mok TS, Chen ZH, et al.: Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitor-resistant Chinese non-small cell lung cancer. Pathol Oncol Res 2009;15:651-658.
6.
Yu HA, Arcila ME, Rekhtman N, et al.: Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 2013;19:2240-2247.
7.
Denis MG, Vallée A, Théoleyre S: EGFR T790M resistance mutation in non small-cell lung carcinoma. Clin Chim Acta 2015;444:81-85.
8.
Kobayashi S, Boggon TJ, Dayaram T, et al.: EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005;352:786-792.
9.
Jänne PA, Yang JC, Kim DW, et al.: AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med 2015;372:1689-1699.
10.
Sequist LV, Soria JC, Goldman JW, et al.: Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med 2015;372:1700-1709.
11.
Bell DW, Gore I, Okimoto RA, et al.: Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nat Genet 2005;37:1315-1316.
12.
Gazdar A, Robinson L, Oliver D, et al.: Hereditary lung cancer syndrome targets never smokers with germline EGFR gene T790M mutations. J Thorac Oncol 2014;9:456-463.
13.
Inukai M, Toyooka S, Ito S, et al.: Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer. Cancer Res 2006;66:7854-7858.
14.
Sequist LV, Martins RG, Spigel D, et al.: First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008;26:2442-2449.
15.
Kim HR, Cho BC, Shim HS, et al.: Prediction for response duration to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutated never smoker lung adenocarcinoma. Lung Cancer 2014;83:374-382.
16.
Li H, Hu H, Wang R, et al.: Primary concomitant EGFR T790M mutation predicted worse prognosis in non-small cell lung cancer patients. Onco Targets Ther 2014;7:513-524.
17.
Li S, Li L, Zhu Y, et al.: Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: A comprehensive mutation profiling from 5125 Chinese cohorts. Br J Cancer 2014;110:2812-2820.
18.
Yu HA, Arcila ME, Hellmann MD, et al.: Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing. Ann Oncol 2014;25:423-428.
19.
Godin-Heymann N, Bryant I, Rivera MN, et al.: Oncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutation. Cancer Res 2007;67:7319-7326.
20.
Mulloy R, Ferrand A, Kim Y, et al.: Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib. Cancer Res 2007;67:2325-2330.
21.
Chmielecki J, Foo J, Oxnard GR, et al.: Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci Transl Med 2011;3:90ra59.
22.
Oxnard GR, Arcila ME, Sima CS, et al.: Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: Distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res 2011;17:1616-1622.
23.
Hata A, Katakami N, Kaji R, et al.: Does T790M disappear? Successful gefitinib rechallenge after T790M disappearance in a patient with EGFR-mutant non-small-cell lung cancer. J Thorac Oncol 2013;8:e27-29.
24.
Sutto L, Gervasio FL: Effects of oncogenic mutations on the conformational free-energy landscape of EGFR kinase. Proc Natl Acad Sci USA 2013;110:10616-10621.
25.
Leone A: Highly sensitive detection of EGFR T790M mutation in pre-TKI specimens of EGFR-mutated NSCLC: In cis, in trans, or a different clone? J Thorac Oncol 2013;8:e26-27.
26.
Fujita Y, Suda K, Kimura H, et al.: Highly sensitive detection of EGFR T790M mutation using colony hybridization predicts favorable prognosis of patients with lung cancer harboring activating EGFR mutation. J Thorac Oncol 2012;7:1640-1644.
27.
Watanabe M, Kawaguchi T, Isa S, et al.: Ultra-sensitive detection of the pretreatment EGFR T790M mutation in non-small cell lung cancer patients with an EGFR-activating mutation using droplet digital PCR. Clin Cancer Res 2015;21:3552-3560.
28.
Xu Q, Zhu Y, Bai Y, et al.: Detection of epidermal growth factor receptor mutation in lung cancer by droplet digital polymerase chain reaction. Onco Targets Ther 2015;8:1533-1541.
29.
Chen LY, Molina-Vila MA, Ruan SY, et al.: Coexistence of EGFR T790M mutation and common activating mutations in pretreatment non-small cell lung cancer: A systematic review and meta-analysis. Lung Cancer 2016;94:46-53.
30.
Rosell R, Molina MA, Costa C, et al.: Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations. Clin Cancer Res 2011;17:1160-1168.
31.
Su KY, Chen HY, Li KC, et al.: Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. J Clin Oncol 2012;30:433-440.
32.
Costa C, Molina MA, Drozdowskyj A, et al.: The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial. Clin Cancer Res 2014;20:2001-2010.
33.
Ding D, Yu Y, Li Z, et al.: The predictive role of pretreatment epidermal growth factor receptor T790M mutation on the progression-free survival of tyrosine-kinase inhibitor-treated non-small cell lung cancer patients: a meta-analysis. Onco Targets Ther 2014;7:387-393.
34.
Lee Y, Lee GK, Lee YS, et al.: Clinical outcome according to the level of preexisting epidermal growth factor receptor T790M mutation in patients with lung cancer harboring sensitive epidermal growth factor receptor mutations. Cancer 2014;120:2090-2098.
35.
Ye X, Zhu ZZ, Zhong L, et al.: High T790M detection rate in TKI-naive NSCLC with EGFR sensitive mutation: Truth or artifact? J Thorac Oncol 2013;8:1118-1120.
36.
Moiseyenko VM, Procenko SA, Levchenko EV, et al.: High efficacy of first-line gefitinib in non-Asian patients with EGFR-mutated lung adenocarcinomas. Onkologie 2010;33:231-238.
37.
Mitiushkina NV, Iyevleva AG, Poltoratskiy AN, et al.: Detection of EGFR mutations and EML4-ALK rearrangements in lung adenocarcinomas using archived cytological slides. Cancer Cytopathol 2013;121:370-376.
38.
Ulybina YM, Kuligina ESh, Mitiushkina NV, et al.: Coding polymorphisms in Casp5, Casp8 and DR4 genes may play a role in predisposition to lung cancer. Cancer Lett 2009;278:183-191.
39.
Milbury CA, Zhong Q, Lin J, et al.: Determining lower limits of detection of digital PCR assays for cancer-related gene mutations. Biomol Detect Quantif 2014;1:8-22.
40.
Li J, Jänne PA, Makrigiorgos G: Biotinylated probe isolation of targeted gene region improves detection of T790M epidermal growth factor receptor mutation via peptide nucleic acid-enriched real-time PCR. Clin Chem 2011;57:770-773.
41.
Hidaka N, Iwama E, Kubo N, et al.: Most T790M mutations are present on the same EGFR allele as activating mutations in patients with non-small cell lung cancer. Lung Cancer 2017;108:75-82.
42.
Kobayashi Y, Mitsudomi T: Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy. Cancer Sci 2016;107:1179-1186.
43.
Do H, Molania R, Mitchell PL, et al.: Reducing artifactual EGFR T790M mutations in DNA from formalin-fixed paraffin-embedded tissue by use of thymine-DNA glycosylase. Clin Chem 2017;63:1506-1514.
44.
Maheswaran S, Sequist LV, Nagrath S, et al.: Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 2008;359:366-377.
45.
Zhao J, Feng HH, Zhao JY, et al.: A sensitive and practical method to detect the T790M mutation in the epidermal growth factor receptor. Oncol Lett 2016;11:2573-2579.
46.
Rosell R, Dafni U, Felip E, et al.: Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): An international, multicentre, single-arm, phase 2 trial. Lancet Respir Med 2017;5:435-444.
47.
Liu Y, Sun L, Xiong ZC, et al.: Meta-analysis of the impact of de novo and acquired EGFR T790M mutations on the prognosis of patients with non-small cell lung cancer receiving EGFR-TKIs. Onco Targets Ther 2017;10:2267-2279.
48.
Ma G, Zhang J, Yin L, et al.: The prognostic role of pretreatment epidermal growth factor receptor T790M mutation in advanced non-small cell lung cancer patients treated with EGFR tyrosine kinase inhibitors. Oncotarget 2017;8:50941-50948
49.
Shields PG: Publication bias is a scientific problem with adverse ethical outcomes: The case for a section for null results. Cancer Epidemiol Biomarkers Prev 2000;9:771-772.
50.
Ioannidis JP, Trikalinos TA, Ntzani EE, Contopoulos-Ioannidis DG: Genetic associations in large versus small studies: An empirical assessment. Lancet 2003;361:567-571.
© 2018 S. Karger GmbH, Freiburg
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.